Search Results - Ranzenigo M

Outcome of Darunavir–Cobicistat-Based Regimens in HIV-Infected People Who Have Experienced Virological Failure by Alberton F, Galli L, Lolatto R, Candela C, Gianotti N, Chiurlo M, Ranzenigo M, Strano M, Uglietti A, Castagna A

Connect to this object online.

Bictegravir/Emtricitabine/Tenofovir Alafenamide Treatment: Efficacy and Tolerability in Clinical Practice by Canetti D, Galli L, Lolatto R, Nozza S, Spagnuolo V, Muccini C, Trentacapilli B, Bruzzesi E, Ranzenigo M, Chiurlo M, Castagna A, Gianotti N

Connect to this object online.

Switching from a Non-Protease inhibitor-Based Regimen To the Fixed Dose Combination of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in Clinical Practice by Ranzenigo M, Gianotti N, Galli L, Poli A, Mastrangelo A, Bruzzesi E, Chiurlo M, Nozza S, Bossolasco S, Spagnuolo V, Mancusi D, Termini R, Carini E, Lazzarin A, Castagna A

Connect to this object online.

Switching from a Non-Protease Inhibitor-Based Regimen to the Fixed Dose Combination of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in Clinical Practice [Corrigendum] by Ranzenigo M, Gianotti N, Galli L, Poli A, Mastrangelo A, Bruzzesi E, Chiurlo M, Nozza S, Bossolasco S, Spagnuolo V, Mancusi D, Termini R, Carini E, Lazzarin A, Castagna A

Connect to this object online.